A new trading day began on Tuesday, with Neumora Therapeutics Inc. (NASDAQ: NMRA) stock price down -1.76% from the previous day of trading, before settling in for the closing price of $11.94. NMRA’s price has ranged from $8.33 to $21.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 58.94%. With a float of $55.23 million, this company’s outstanding shares have now reached $158.83 million.
Let’s look at the performance matrix of the company that is accounted for 124 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc. (NMRA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Neumora Therapeutics Inc. is 65.49%, while institutional ownership is 27.62%. The most recent insider transaction that took place on Sep 17 ’24, was worth 363,734. Before that another transaction happened on Sep 12 ’24, when Company’s Head of R&D sold 32,948 for $11.43, making the entire transaction worth $376,665. This insider now owns 369,993 shares in total.
Neumora Therapeutics Inc. (NMRA) Latest Financial update
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -1.14 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 58.94% per share during the next fiscal year.
Neumora Therapeutics Inc. (NASDAQ: NMRA) Trading Performance Indicators
Here are Neumora Therapeutics Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 17.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.74, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.60 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc. (NMRA)
Neumora Therapeutics Inc. (NASDAQ: NMRA) saw its 5-day average volume 0.7 million, a positive change from its year-to-date volume of 0.6 million. As of the previous 9 days, the stock’s Stochastic %D was 72.60%. Additionally, its Average True Range was 0.65.
During the past 100 days, Neumora Therapeutics Inc.’s (NMRA) raw stochastic average was set at 66.92%, which indicates a significant increase from 65.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.81% in the past 14 days, which was higher than the 54.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.63, while its 200-day Moving Average is $12.85. Nevertheless, the first resistance level for the watch stands at $12.02 in the near term. At $12.31, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.52. If the price goes on to break the first support level at $11.52, it is likely to go to the next support level at $11.31. The third support level lies at $11.02 if the price breaches the second support level.
Neumora Therapeutics Inc. (NASDAQ: NMRA) Key Stats
With a market capitalization of 1.88 billion, the company has a total of 159,524K Shares Outstanding. Currently, annual sales are 0 K while annual income is -235,930 K. The company’s previous quarter sales were 0 K while its latest quarter income was -58,700 K.
